Covid19
Conditions
Keywords
SARS-CoV-2, Adjuvanted inactivated vaccine
Brief summary
This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first low dose group, followed by high dose group) and placebo arm.
Detailed description
This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first low dose group, followed by high dose group) and placebo arm. Each dose of vaccine will be defined as a cohort in itself, with vaccine administration to 20 participants and placebo administration to 5 participants. After completion of low-dose group, decision of switch to high-dose will be taken by the Independent Data Monitoring Committee and will continue accordingly. In the study, 50 healthy participants of 18-45 years of age will be recruited. All injections will be done subcutaneously. Injections will be administered at 1 and 21 days. The participants will be followed for 6 months and the study will be completed in 12 months.
Interventions
BIOLOGICALSARS-CoV-2 vaccine
Adjuvanted inactivated vaccine
BIOLOGICALPlacebo
0.9% NaCl
Sponsors
The Scientific and Technological Research Council of Turkey
VETAL Inc.
MonitorCRO
Osman ERGANIS, PhD, Prof
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Masking description
Double-blinded
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
To be eligible for the study, each participant must satisfy all the following criteria: 1. Healthy participants between 18-45 years of age, 2. Sign an informed consent document, 3. Negative immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody for COVID-19, 4. Negative quantitative polymerase chain reaction (qPCR) SARS-CoV-2 results of nasopharyngeal/sputum samples, 5. Able to comply with the study protocol during the study period, 6. Negative tests for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), 7. Body temperature \<37.2 C and no signs of active infection, 8. Body mass index 18-35 kg/m2, 9. Normal laboratory levels of whole blood count, alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, urea, creatinine, and fasting blood glucose, or abnormal finding detected in any laboratory parameter which is not greater than Grade 1 according to the investigator's evaluation, 10. Good general health (no known disease in the history and physical examination within 14 days prior to the enrolment), 11. Female and male participants who will be able to have appropriate contraception methods within 30 days prior to vaccine injection and within 6 months after vaccination,
Exclusion criteria
Participants with any of the following criteria will be excluded: 1. History of seizure, encephalopathy, or psychosis, 2. History of allergic reactions to any known vaccine or to any component of the study vaccine, 3. Pregnant, breastfeeding, or positive pregnancy test or planning to conceive within 6 months, 4. History of SARS-CoV-2 infection, 5. Severe cardiovascular disorders (arrhythmia, conduction disorders, history of myocardial infarction, uncontrolled hypertension), 6. Severe chronic disorders (asthma, diabetes mellitus, thyroid disorders…etc), 7. Congenital or acquired angioedema, 8. Diagnosis of immunodeficiency, 9. Diagnosis of bleeding diathesis, 10. Use of immunosuppressive treatment, anti-allergic treatment, cytotoxic treatment, inhaler corticosteroids (allergic rhinitis or topical steroid ointments are excluded), 11. Those who received blood and blood product transfusions in the last 6 months, 12. Those on any vaccine program or experimental medication within 1 month prior to the study, 13. History of any vaccination against SARS-CoV-2 within 1 month prior to the study, 14. Use of active tuberculosis treatment, 15. History of addictive drug use, 16. History of alcohol abuse and/or history of alcohol intake more than 2 units per day or 10 units per week and/or positive breath alcohol test (one unit of alcohol equals to 250 mL beer, 125 mL wine or 25 mL whiskey), 17. According to the investigator's evaluation, those who have any condition (medical, psychological, social, etc.) that may impair the patient's compliance with the study will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acute adverse events (AEs) | 24 hours | Frequency of acute adverse events in all dosage groups |
| Solicited local and systemic adverse events (AEs) | 15 days | Frequency of local and systemic AEs in all dosage groups |
| Unsolicited local and systemic adverse events (AEs) | 28 days | Frequency of local and systemic AEs in all dosage groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neutralizing antibody response | Before first dose administration, on Day 21-28-35 and Month 3 and Month 6 after first dose administration. | Immunogenicity response by measuring neutralizing antibody titer (anti-spike and anti-RBD) developed against SARS-CoV-2 (by ELISA) |
| Cellular immune response | Before first dose administration, on Day 21-28-35 and Month 3 and Month 6 after first dose administration. | Interferon-γ (IFN-γ) positive cell level (by ELISPOT) |
Countries
Turkey (Türkiye)
Outcome results
None listed